MGMT and central nervous system cancer: This longitudinal pilot study, though non-randomized and non-blinded, aims to assess whether the combined use of CUR and PD with standard therapies improves survival and quality of life in patients with GBM (diagnosed only by histological examination and MGMT promoter molecular study alone, with a classification of WHO grade 4 glioma).